MA55718A - Méthodes de traitement du cancer du rein avec un anticorps anti-psma/cd3 - Google Patents

Méthodes de traitement du cancer du rein avec un anticorps anti-psma/cd3

Info

Publication number
MA55718A
MA55718A MA055718A MA55718A MA55718A MA 55718 A MA55718 A MA 55718A MA 055718 A MA055718 A MA 055718A MA 55718 A MA55718 A MA 55718A MA 55718 A MA55718 A MA 55718A
Authority
MA
Morocco
Prior art keywords
psma
antibody
methods
kidney cancer
treating kidney
Prior art date
Application number
MA055718A
Other languages
English (en)
Inventor
Theresa Mcdevitt
Shoba Shetty
Hong Xie
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55718A publication Critical patent/MA55718A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055718A 2019-04-19 2020-04-17 Méthodes de traitement du cancer du rein avec un anticorps anti-psma/cd3 MA55718A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962836287P 2019-04-19 2019-04-19

Publications (1)

Publication Number Publication Date
MA55718A true MA55718A (fr) 2022-02-23

Family

ID=70465165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055718A MA55718A (fr) 2019-04-19 2020-04-17 Méthodes de traitement du cancer du rein avec un anticorps anti-psma/cd3

Country Status (13)

Country Link
US (1) US20210079115A1 (fr)
EP (1) EP3956023A1 (fr)
JP (1) JP2022529970A (fr)
KR (1) KR20220002900A (fr)
CN (1) CN113747945A (fr)
AR (1) AR118721A1 (fr)
AU (1) AU2020259405A1 (fr)
BR (1) BR112021020873A2 (fr)
CA (1) CA3136892A1 (fr)
MA (1) MA55718A (fr)
MX (1) MX2021012765A (fr)
TW (1) TW202104266A (fr)
WO (1) WO2020212949A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113747944A (zh) 2019-04-19 2021-12-03 詹森生物科技公司 用抗psma/cd3抗体治疗前列腺癌的方法
EP4392454A4 (fr) * 2021-08-27 2025-10-15 Janssen Biotech Inc Anticorps anti-psma et leurs utilisations
US20250304714A1 (en) * 2022-05-16 2025-10-02 Regeneron Pharmaceuticals, Inc. Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
EP3106468A1 (fr) * 2008-10-01 2016-12-21 Amgen Research (Munich) GmbH Anticorps bispécifique à chaîne unique psmaxcd3 particulière d'une espèce à l'autre
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PE20211916A1 (es) * 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos

Also Published As

Publication number Publication date
WO2020212949A1 (fr) 2020-10-22
BR112021020873A2 (pt) 2022-04-19
AU2020259405A1 (en) 2021-09-23
CN113747945A (zh) 2021-12-03
MX2021012765A (es) 2021-11-18
AR118721A1 (es) 2021-10-27
US20210079115A1 (en) 2021-03-18
JP2022529970A (ja) 2022-06-27
EP3956023A1 (fr) 2022-02-23
TW202104266A (zh) 2021-02-01
KR20220002900A (ko) 2022-01-07
CA3136892A1 (fr) 2020-10-22

Similar Documents

Publication Publication Date Title
MA55717A (fr) Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
EP3752180A4 (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
EP3752193A4 (fr) Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MX2022002682A (es) Anticuerpos anti-cd73.
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
EP3573658A4 (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
MA55718A (fr) Méthodes de traitement du cancer du rein avec un anticorps anti-psma/cd3
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
IL286641A (en) Engineered iga antibodies and methods of use
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
EA201992460A1 (ru) Антитела-агонисты btla и их применение
IL285308A (en) Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer